The precision medicine (PM) initiative is a response to the dismal outlook in solid cancer. Despite heterogeneity, common mechanistic denominators may exist across the spectrum of solid cancer. A shift from conventional research and development (R&D) toward PM will require conceptual and structural change. As individuals and as a society, we welcome innovation, but question change. We ask: In solid cancer, does PM identify and address the causes of prior failures, and, if so, are the proposed solutions feasible? And, when may we expect safer, more effective and affordable drugs in the clinic? Considerations that prompt a pragmatic rethink include a failure analysis of translational R&D in solid cancer suggesting that trials and regulations need to be aligned with the natural history of the disease. In successful therapeutic interventions in chronic, complex disease, surrogate markers and endpoints should be consistent with the Prentice's criteria. In solid cancer, drug induced tumor shrinkage, is a drug effect and not a disease response; tumor shrinkage does not reflect nor predict interruption of the disease. Overall, we support a pragmatic, multidisciplinary, and collaborative R&D, and suggest that direction be set by clinical need and utility, and by questions, not answers. PM will prove worthwhile if it could improve clinical outcomes. The lag in therapeutics relative to diagnostics is a cause for confusion. Overdiagnosis adds to fear and harm, especially in the absence of effective interventions. A revised initiative that prioritizes metastasis research could replicate the successful HIV/AIDS model in solid cancer. A pragmatic approach may further translational efforts toward meaningfully effective, generally available, and affordable solutions.

Department of Cell Biology Faculty of Science Charles University Prague Prague 2 Czech Republic

Medbase Chapel Hill NC USA

Zobrazit více v PubMed

Leek JT, Peng RD. What is the question? Science. 2015;347(6228):1314–1315. PubMed

Brábek J, Fernandes M. Affordable cancer care. Lancet Oncol. 2012;13(1):2–3. PubMed

Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795. PubMed PMC

Avorn J, Kesselheim AS. The 21st Century Cures Act – will it take us back in time? N Engl J Med. 2015;372(26):2473–2475. PubMed

Wild CP, Bucher JR, de Jong BW, et al. Translational cancer research: balancing prevention and treatment to combat cancer globally. J Natl Cancer Inst. 2015;107:dju353. PubMed PMC

Khoury MJ, Evans JP. A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit. JAMA. 2015;313(21):2117–2118. PubMed PMC

Salari K, Watkins H, Ashley EA. Personalized medicine: hope or hype? Eur Heart J. 2012;33(13):1564–1570. PubMed PMC

Blumenthal D, Abrams M, Nuzum R. The Affordable Care Act at 5 years. N Engl J Med. 2015;372(25):2451–2458. PubMed

Topol EJ. Individualized medicine from prewomb to tomb. Cell. 2014;157(1):241–253. PubMed PMC

Rubin R. Precision medicine: the future or simply politics? JAMA. 2015;313(11):1089–1091. PubMed

Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfill the promise of personalised medicine. Lancet. 2015;385(9982):2118–2119. PubMed PMC

Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature. 2015;526(7573):336–342. PubMed PMC

Jameson JL, Longo DL. Precision medicine – personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234. PubMed

Doshi P. 21st century cures: is US medicines bill a colossal mistake? BMJ. 2015:351. PubMed

Janssens AC, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet. 2008;17(R2):R166–R173. PubMed

Joyner MJ, Paneth N. Seven questions for personalized medicine. JAMA. 2015;314(10):999–1000. PubMed

Bradford Hill A. The environment and disease: association or causation. Proc R Soc Med. 1965;58:295–300. PubMed PMC

Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30(3):427–432. PubMed

Vineis P. A self-fulfilling prophecy: are we underestimating the role of the environment in gene–environment interaction research? Int J Epidemiol. 2004;33(5):945–946. PubMed

Kuhn TS. The Structure of Scientific Revolutions. 50th Anniversary edition. Chicago, IL: University of Chicago Press; 2012.

DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366(23):2207–2214. PubMed PMC

Hoag H. Cancer drugs should add months, not weeks, say experts. Nature Med. 2011;17(1):7. PubMed

Ward A. Healthcare: counting the cost of cancer. Financial Times. 2015 Jan 15;

Mailankody S, Prasad V. Five years of cancer drug approvals innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539–540. PubMed

Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186–1193. PubMed

Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J Med. 2003;349(24):2283–2285. PubMed

Volberding P. The impact of HIV research on health outcome and healthcare policy. Ann Oncol. 2011;22(Suppl 7):50–53. PubMed

Piot P, Quinn TC. Response to the AIDS pandemic – a global health model. N Engl J Med. 2013;368(23):2210–2218. PubMed PMC

Edmondson AC. Strategies for learning from failure. Harvard Bus Rev. 2011;89(4):48–55. PubMed

Hall WD, Mathews R, Morley KI. Being more realistic about the public health impact of genomic medicine. PLoS Med. 2010;7(10):e1000347. PubMed PMC

Bayer R, Galea S. Public health in the precision-medicine era. N Engl J Med. 2015;373(6):499–501. PubMed

Burton PR, Tobin MD, Hopper JL. Key concepts in genetic epidemiology. Lancet. 2005;366(9489):941–951. PubMed

Ananthakrishnan R, Menon S. Design of oncology clinical trials: a review. Crit Rev Oncol Hematol. 2013;88(1):144–153. PubMed

Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013;12(5):358–369. PubMed

Marzuillo C, De Vito C, D’Andrea E, Rosso A, Villari P. Predictive genetic testing for complex diseases: a public health perspective. QJM. 2014;107(2):93–97. PubMed PMC

Arnedos M, Soria JC, Andre F, Tursz T. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat Rev. 2014;40(10):1192–1198. PubMed

Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012;9(9):542–548. PubMed

Stahel R, Bogaerts J, Ciardiello F, et al. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. Cancer Treat Rev. 2015;41(2):129–135. PubMed

Ciardiello F, Arnold D, Casali PG, et al. Delivering precision medicine in oncology today and in future – the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO) Ann Oncol. 2014;25(9):1673–1678. PubMed

Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110:551–555. PubMed PMC

Kocher R, Roberts B. The calculus of cures. N Engl J Med. 2014;370:1473–1475. PubMed

Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. Whatever happened to N-of-1 trials? Insiders’ perspectives and a look to the future. Milbank Q. 2008;86(4):533–555. PubMed PMC

Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–611. PubMed

Collette L, Tombal B. N-of-1 trials in oncology. Lancet Oncol. 2015;16:885–886. PubMed

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1. Eur J Cancer. 2009;45(2):228–247. PubMed

Ganten MK, Ganten TM, Schlemmer HP. Radiological monitoring of the treatment of solid tumors in practice. Fortschr Röntgenstr. 2014;186(5):466–473. PubMed

Fernandes M, Rosel D, Brábek J. Translation in solid cancer: are size-based response criteria an anachronism? Clin Transl Oncol. 2015;17:1–10. PubMed

Coche E. Recist and beyond. JBR-BTR. 2013;96:167–171. PubMed

Diederich S. Imaging beyond RECIST: CT and MRI in molecular therapies. Cancer Imaging. 2012;12:347–350. PubMed PMC

Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society. Br J Cancer. 2004;90(12):2256–2260. PubMed PMC

Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104(20):1534–1541. PubMed PMC

Krajewski KM, Franchetti Y, Nishino M, et al. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014;19(5):507–514. PubMed PMC

Chen HX, Rubinstein LV, Shankar LK, Abrams JS. Are we ready for the 10% solution? Oncologist. 2014;19(5):439–440. PubMed PMC

Höink AJ, Heindel W, Buerke B. Radiological evaluation of the therapeutic response of malignant diseases: status quo, innovative developments and requirements for radiology. Fortschr Röntgenstr. 2014;186(10):927–936. PubMed

Fernandes M. Judging a cancer drug: Avastin’s story [letter] New York Times. 2011;160(55423) section A.

Gwyther SJ, Schwartz LH. How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer. 2008;44(1):39–45. PubMed

Bidard F-C, Pierga J-Y, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic – progress and pitfalls. Nat Rev Clin Oncol. 2013;10(3):169–179. PubMed

Fein MR, Egeblad M. Caught in the act: revealing the metastatic process by live imaging. Dis Model Mech. 2013;6(3):580–593. PubMed PMC

Mankoff DA, Farwell MD, Clark AS, Pryma DA. How imaging can impact clinical trial design: molecular imaging as a biomarker for targeted cancer therapy. Cancer J. 2015;21(3):218–224. PubMed

Li C. A targeted approach to cancer imaging and therapy. Nat Mater. 2014;13(2):110–115. PubMed PMC

Jung KH, Lee KH. Molecular imaging in the era of personalized medicine. J Pathol Transl Med. 2015;49(1):5–12. PubMed PMC

Ensor JE. Biomarker validation: common data analysis concerns. Oncologist. 2014;19(8):886–891. PubMed PMC

Aronson JK. Research priorities in biomarkers and surrogate end-points. Br J Clin Pharmacol. 2012;73(6):900–907. PubMed PMC

Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled. Ann Intern Med. 1996;125(7):605–613. PubMed

Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431–440. PubMed

Berger VW. Does the Prentice criterion validate surrogate endpoints? Statist Med. 2004;23(10):1571–1578. PubMed

Huber P, Howard P. What failed, the new cancer treatment or regulators? The Wall Street Journal. 2015 Feb 3;

Bertuzzi S, Cleveland DW. The curious incident of the translational dog that didn’t bark. Trends Cell Biol. 2015;25(4):187–189. PubMed PMC

Wilson MK, Collyar D, Chingos DT, et al. Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol. 2015;16(1):e43–e52. PubMed

Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer. 2010;46(7):1177–1180. PubMed PMC

Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742–1757. PubMed PMC

Weber GF. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett. 2013;328(2):207–211. PubMed

Elvin P, Garner AP. Tumour invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol. 2005;5(4):374–381. PubMed

Fabbro D, Cowan-Jacob SW, Moebitz H. Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol. 2015;172(11):2675–2700. PubMed PMC

Ordóñez-Morán P, Huelsken J. Complex metastatic niches: already a target for therapy? Curr Opin Cell Biol. 2014;31:29–38. PubMed

Pein M, Oskarsson T. Microenvironment in metastasis: roadblocks and supportive niches. Am J Physiol Cell Physiol. 2015;309(10):C627–C638. PubMed

Brabek J, Mierke CT, Rosel D, Vesely P, Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal. 2010;8:22. PubMed PMC

Sleeman JP, Christofori G, Fodde R, et al. Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol. 2012;22(3):174–186. PubMed

Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479–497. PubMed

Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013;34(5):283–289. PubMed PMC

Kosla J, Paňková D, Plachý J, et al. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. Mol Cancer Res. 2013;11(10):1235–1247. PubMed

Bordeleau F, Alcoser TA, Reinhart-King CA. Physical biology in cancer. 5. The rocky road of metastasis: the role of cytoskeletal mechanics in cell migratory response to 3D matrix topography. Am J Physiol Cell Physiol. 2014;306(2):C110–C120. PubMed PMC

Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–439. PubMed PMC

Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol. 2014;171(24):5507–5523. PubMed PMC

Matsuoka T, Yashiro M. Rho/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol. 2014;20(38):13756–13766. PubMed PMC

Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27(20):2192–2206. PubMed PMC

Steeg PS, Anderson RL, Bar-Eli M, et al. An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis. Clin Cancer Res. 2009;15:4529–4530. PubMed PMC

Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. PNAS. 2003;100(13):7737–7742. PubMed PMC

Klein CA. The metastatic cascade. Science. 2008;321(5897):1785–1787. PubMed

Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell. 2003;4(1):4–6. PubMed

Brábek J, Fernandes M. Reasons for the R&D crisis. The Scientist. Sep 23, 2013. [Accessed March 4, 2016]. Available from: http://www.the-scientist.com/?articles.view/articleNo/37522/title/Opinion-Reasons-for-the-R-D-Crisis/

Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 2010;10(4):232–233. PubMed

Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28. PubMed

Tolde O, Rösel D, Veselý P, Folk P, Brábek J. The structure of invadopodia in a complex 3D environment. Eur J Cell Biol. 2010;89(9):674–680. PubMed

Burton H, Sagoo GS, Pharoah P, Zimmern RL. Time to revisit Geoffrey Rose: strategies for prevention in the genomic era? Italian J Public Health. 2012;9(4):e8665, 1–9.

Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res. 2012;18(1):23–32. PubMed

Horwitz RI, Cullen MR, Abell J, Christian JB. (De)personalized medicine. Science. 2013;339(6124):1155–1156. PubMed

Murray JF. Personalized medicine: been there, done that, always needs work! Am J Respir Crit Care Med. 2012;185(12):1251–1252. PubMed

Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803–1805. PubMed

Garaway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806–1814. PubMed

Tannock I. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Eur Urol. 2014;65(4):846–847. PubMed

Izar B, Rotow J, Gainor J, Clark J, Chabner B. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. Pharmacol Rev. 2013;65(4):1351–1395. PubMed

Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. PNAS. 2008;105(8):3041–3046. PubMed PMC

Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873–886. PubMed

Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. PubMed PMC

Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772–774. PubMed

Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol. 2006;33(4):407–420. PubMed

Sawyers CL. Combined forces. Nature. 2013;498(7455):S7. PubMed

Komarova NL, Boland CR. Cancer: calculated treatment. Nature. 2013;499(7458):291–292. PubMed PMC

Goldie JH. Drug resistance in cancer: a perspective. Cancer Metastasis Rev. 2001;20(1–2):63–68. PubMed

Fabbro D. 25 Years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol. 2015;87(5):766–775. PubMed

Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression – implications for drug resistance. Nat Rev Clin Oncol. 2013;10(10):571–587. PubMed PMC

Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32:92. PubMed PMC

Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258–1266. PubMed PMC

Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–1182. PubMed PMC

Nishida T, Doi T. Rechallenge of drugs in the era of targeted therapy. Lancet Oncol. 2013;14(12):1143–1145. PubMed

Auliac JB, Fournier C, Audigier Valette C, et al. Impact of continuing first-line EGFR tyrosine kinase inhibitor therapy beyond RECIST disease progression in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC): retrospective GFPC 04-13 study. Target Oncol. 2015 Aug 29; Epub. PubMed

Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg. 2013;100(1):55–65. PubMed

Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):234–242. PubMed PMC

Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr. 2014;49:187–197. PubMed PMC

Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;49:145–186. PubMed PMC

Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic” – screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–1767. PubMed

Ahn HS, Welch HG. South Korea’s thyroid-cancer “epidemic” – turning the tide. N Engl J Med. 2015;373(24):2389–2390. PubMed

Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med. 2000;343(2):141–144. PubMed

Welch HG, Albertsen PC. Why doctors shouldn’t be punished for giving prostate tests. The New York Times. 2016 Jan 7;

Rose G, Day S. The population mean predicts the number of deviant individuals. BMJ. 1990;301(6759):1031–1034. PubMed PMC

Keyes KM, Davey Smith G, Koenen KC, Galea S. The mathematical limits of genetic prediction for complex chronic disease. J Epidemiol Commun Health. 2015;69(6):574–579. PubMed PMC

Gonsalves G, Harrington M, Kessler DA. Don’t weaken the FDA’s drug approval process. The New York Times. 2015 Jun 11;

Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clinic Proc. 2015;90(8):996–1000. PubMed PMC

Young RC. Value-based cancer care. N Engl J Med. 2015;373(27):2593–2595. PubMed

Bunnik EM, Schermer MH, Janssens AC. Naming and framing in genomic testing. Trends Mol Med. 2014;20(2):63–65. PubMed

Brandt AM. How AIDS invented global health. N Engl J Med. 2013;368(23):2149–2152. PubMed

Joyner MJ. “Moonshot” medicine will let us down. New York Times. 2015 Jan 29;

Jalali R, Mittra I, Badwe R. Cancer research: in need of introspection. Lancet Oncol. 2016;17:140–141. PubMed

Dyson FJ. Is science mostly driven by ideas or by tools? Science. 2012;338(6113):1426–1427. PubMed

Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(S1):S144–S150. PubMed

Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell diseasesummary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048. PubMed

Bentires-Alj M, Rajan A, van Harten W, et al. Stimulating translational research: several European life science institutions put their heads together. Trends Mol Med. 2015;21(9):525–527. PubMed

James W. Pragmatism: A New Name for Some Old Ways of Thinking. London, UK: Longman, Green & Co; 1907.

Rösel D, Brábek J, Veselý P, Fernandes M. Drugs for solid cancer: the productivity crisis prompts a rethink. Onco Targets Ther. 2013;6:767–777. PubMed PMC

Valent P, Groner B, Schumacher U, et al. Paul Ehrlich (1854–1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun. 2016 Feb 5; Epub. PubMed PMC

Ledford H. Big Science: the cancer genome challenge. Nature. 2010;464(7291):972–974. PubMed

Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012;4(133):133ra58. PubMed PMC

Matuchansky C. The promise of personalised medicine. Lancet. 2015;386(9995):742. PubMed

Doble B, Schofield DJ, Roscioli T, Mattick JS. The promise of personalised medicine. Lancet. 2016;387(10017):433–434. PubMed

Olive KP. Stroma, stroma everywhere (far more than you think) Clin Cancer Res. 2015;21(15):3366–3368. PubMed PMC

Glentis A, Gurchenkov V, Matic Vignjevic D. Assembly, heterogeneity, and breaching of the basement membranes. Cell Adh Migr. 2014;8(3):236–245. PubMed PMC

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. PubMed

Panková K, Rösel D, Novotný M, Brábek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci. 2010;67(1):63–71. PubMed PMC

Somarelli JA, Schaeffer D, Marengo MS, et al. Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways. Oncogene. 2016 Jan 11; Epub. PubMed PMC

Sada M, Ohuchida K, Horioka K, et al. Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Cancer Lett. 2016;372(2):210–218. PubMed

Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21(15):3561–3568. PubMed PMC

Cox TR, Erler JT. Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin Cancer Res. 2014;20(14):3637–3643. PubMed

Unbekandt M, Croft DR, Crighton D, et al. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Commun Signal. 2014;12:54. PubMed PMC

Sadok A, McCarthy A, Caldwell J, et al. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res. 2015;75(11):2272–2284. PubMed

Kale VP, Hengst JA, Desai DH, et al. A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion. Cancer Lett. 2015;361(2):185–196. PubMed PMC

Solid cancer: the new tumour spread endpoint opens novel opportunities